OR WAIT 15 SECS
GE Healthcare’s Dharmacon business and CordenPharma contract manufacturing enter a strategic collaboration to accelerate the oligonucleotide development process.
CordenPharma International and GE Healthcare’s Dharmacon business announced on June 28, 2017 a collaboration to facilitate the speed and capacity challenges researchers involved in oligonucleotide-based drug discovery face when transitioning from research and preclinical stages to drug development and clinical trials. The companies will provide biotech and pharmaceutical customers with a new option to move from a technology vendor to a contract manufacturing organization.
“Through this agreement, we are bringing GE Healthcare’s Dharmacon product line, which offers leading technical expertise in research-scale design and manufacturing, together with CordenPharma’s deep experience in contract manufacturing,” said Olivier Loeillot, general manager of GE Healthcare’s genomics and cellular research business in a press release announcing the agreement. “We can help customers move faster by working together and provide an offering that takes them from bench to batch with one partner.”
“This collaboration will further strengthen our newly created service offering in the oligonucleotide manufacturing field and will uniquely position CordenPharma and Dharmacon in this growing pharmaceutical market segment” said Michael Quirmbach, CordenPharma international VP of global marketing and sales, in the release. “Customers will be able to benefit from an efficient end-to-end solution, including drug-product supply."